Ixchelsis CEO, Gary Muirhead attended BioTrinity in London, May 08-10 2017. Please contact us through the website for further information.
May 2017: Ixchelsis CEO Gary Muirhead Attended BioTrinity May 08th -10th 2017
May 3, 2017 by
Innovators in Reproductive Health
Latest News
May 2017: Members of the Ixchelsis Scientific Advisory Board Present Clinical Results for a Study of IX-01 in Men with PE at American Urological Association Meeting. Boston May 12th -16th 2017
Ixchelsis is pleased to announce that two abstracts relating to the results of the proof of concept trial (PEPIX) of IX-01 in men with lifelong premature ejaculation were accepted … [Read More...]
May 2017: Ixchelsis CEO Gary Muirhead Attended BioTrinity May 08th -10th 2017
Ixchelsis CEO, Gary Muirhead attended BioTrinity in London, May 08-10 2017. Please contact us through the website for further information. … [Read More...]
February 2017: Ixchelsis Announces Start of Phase II B Dose Range-Finding Study for IX-01
Following the positive proof-of-concept data released in 2016, Ixchelsis is pleased to announce the start of the Phase II B dose range-finding study for IX-01 in February 2017. The … [Read More...]